ASH 2020

Complete Coverage

Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML

By

Lauren Dembeck, PhD

Publish Date December 11, 2020

Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.

Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date December 11, 2020

A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.

Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date December 11, 2020

The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.

Does Prior TKI Therapy Affect Outcomes in R/R AML Treated With Gilteritinib?

By

Lauren Dembeck, PhD

Publish Date December 11, 2020

Investigators retrospectively assessed whether previous TKI therapy may affect response and survival outcomes in patients with relapsed or refractory acute myeloid leukemia.

Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL

By

Leah Lawrence

Publish Date December 9, 2020

The bispecific CAR-T therapy targets CD20 and CD19.

Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date December 9, 2020

Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.

CAR-T Product With Unique Manufacturing Process Appears Safe in the Outpatient Setting

By

Christina Bennett, MS

Publish Date December 9, 2020

A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.

Fully Human BCMA-Directed CAR-T Shows High Response Rate in Myeloma

By

Christina Bennett, MS

Publish Date December 9, 2020

A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.

Sustained CLL Response Seen With Ibrutinib Plus Venetoclax After MRD Negativity

By

Leah Lawrence

Publish Date December 9, 2020

Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.

Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD

By

Leah Lawrence

Publish Date December 9, 2020

Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.